Mimovirus: a Novel Form of Vaccine That Induces Hepatitis B Virus-Specific Cytotoxic T-Lymphocyte Responses In Vivo

Wu, Yuzhang; Zhao, Jianping; Wan, Ying; Jia, Zhengcai; Zhou, Weiping; Bian, Jiang; Ni, Bing; Zou, Liyun; Tang, Yan

doi:10.1128/jvi.76.20.10264-10269.2002

Cited by 18 publications

(12 citation statements)

References 39 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, epitope-based peptides alone cannot elicit competent immune responses (Naz et al 2005). Research has reported that mimovirus vaccines with sizes similar to viruses can induce cellular immunity (Wu et al 2002, Yang et al 2008. Other studies also have indicated that mimovirus vaccines induce cellular and humoral immune responses (Zhang et al 2008).…”

Section: Discussionmentioning

confidence: 99%

“…Construction of mimovirus took place as described previously (Wu et al 2002). Briefly, the mimovirus was prepared in microcentrifuge tubes by adding plasmids P1 and P2 to TAT [49][50][51][52][53][54][55][56][57] with different molar ratios (0, 0.5, 1, 2, 4, 8, and 16) in HEPES-buffered saline containing 10 mM HEPES and 150 mM NaCl.…”

Section: Construction and Identification Of Mimovirusmentioning

confidence: 99%

“…The input molar ratio (r) of peptide to DNA plasmid was the ratio of moles of lysine to nucleotide (NH4 C /PO 3 ). The mimovirus was identified by a DNA retardation assay, DNaseI digestion assay, transmission electron microscopy, and particle size analysis as described previously (Wu et al 2002). Mimovirus1 was produced by a combination of cationic peptide TAT 49-57 SPINLW1 103-115 and plasmid P1.…”

Section: Construction and Identification Of Mimovirusmentioning

confidence: 99%

“…Previous studies have also shown that this B-cell epitope can induce a SPINLW1-dominant B-cellepitope-specific immune response and suppress fertility (Chen et al 2009). For this reason, a mimovirus vaccine strategy was developed and carried out to improve upon the immune potential of this B-cell epitope as a vaccine immunogen (Wu et al 2002). This nanometer-sized particle antigen delivery system was constructed by combination of the epitope from SPINLW1 and the plasmid encoding the same epitope.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Induction of specific immune response and suppression of fertility by B-cell-epitope-based mimovirus vaccine

Shen¹,

Wang²,

Zhang³

et al. 2011

Reproduction

Self Cite

View full text Add to dashboard Cite

SPINLW1 (previously known as eppin (epididymal protease inhibitor)) is a target under intense scrutiny in the study of male contraceptive vaccines. B-cell-dominant epitopes are now recognized as key parts of the induction of humoral immune responses against target antigens. The generation of robust humoral responses in vivo has become a crucial problem in the development of modern vaccines. In this study, we developed a completely novel B-cell-dominant-epitope-based mimovirus vaccine, which is a kind of virus-size particulate antigen delivery system. The mimovirus successfully self-assembled from a cationic peptide containing a cell-penetrating peptide of TAT 49-57 and a plasmid DNA encoding both three SPINLW1 (103-115) copies and adjuvant C3d3. The male mice were immunized with the epitope-based mimovirus vaccine, which resulted in a gradual elevation of specific serum IgG antibody levels. These reached a peak at week 4. Mating for the fertility assay showed that the mimovirus vaccine had accomplished a moderate fertility inhibition effect and investigation into the mechanism of action showed that it did so by interfering with the reproductive function of the sperm but that it did not damage the structures of the testes or cause serum testosterone to decline. Our results suggest an ideal protocol for suppressing fertility in mice by an engineered mimovirus vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Construction and Identification Of Mimovirusmentioning

confidence: 99%

Section: Construction and Identification Of Mimovirusmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Induction of specific immune response and suppression of fertility by B-cell-epitope-based mimovirus vaccine

Shen¹,

Wang²,

Zhang³

et al. 2011

Reproduction

Self Cite

View full text Add to dashboard Cite

show abstract

“…Wu et al [43] also developed an innovative minovirus vaccine to induce hepatitis B virus specific cytotoxic T-lymphocyte responses. They proved that their mimovirus could induce an HBsAg28-39-specific CTL response in vivo.…”

Section: Therapeutic Vaccinationmentioning

confidence: 99%

Novel approaches towards conquering hepatitis B virus infection

Wu¹

2007

WJG

View full text Add to dashboard Cite

Currently approved treatments for hepatitis B virus (HBV) infection include the immunomodulatory agent, IFN-α, and nucleos(t)ide analogues. Their efficacy is limited by their side effects, as well as the induction of viral mutations that render them less potent. It is thus necessary to develop drugs that target additional viral antigens. Chemicals and biomaterials by unique methods of preventing HBV replication are currently being developed, including novel nucleosides and newly synthesized compounds such as capsid assembling and mRNA transcription inhibitors. Molecular therapies that target different stages of the HBV life cycle will aid current methods to manage chronic hepatitis B (CHB) infection. The use of immunomodulators and gene therapy are also under consideration. This report summarizes the most recent treatment possibilities for CHB infection. Emerging therapies and their potential mechanisms, efficacy, and pitfalls are discussed.

show abstract

Long‐term persistence of hepatitis B surface antigenand antibody induced by DNA‐mediated immunization results in liver and kidney lesions in mice

Yao

Zhu

et al. 2006

Eur J Immunol

View full text Add to dashboard Cite

DNA-mediated immunization has been recognized as a new approach for prevention and treatment of hepatitis B virus (HBV) infection. However, the side effects of this approach have not been well described. Here we report that DNA-mediated immunization by intramuscular injection of plasmid DNA encoding HBV surface antigen (HBsAg) induced long-term persistence of HBsAg and HBsAg-specific antibody (anti-HBs) in the sera of the immunized BALB/c mice and resulted in liver and kidney lesions. The lesions persisted for 6 months after injection. Lesions were also found in normal mice injected with the sera from immunized mice, and in HBV-transgenic mice injected with anti-HBs antibody, or sera from immunized mice. Furthermore, lesions were accompanied by deposition of circulating immune complex (CIC) of HBsAg and anti-HBs antibody in the damaged organs. These results indicate that long-term persistence of HBsAg and anti-HBs in the immunized mice can result in deposited CIC in liver and kidney, and in development of lesions. The use of DNA containing mammalian replication origins, such as the plasmids used in this study, is not appropriate for human vaccines due to safety concerns relating to persistence of DNA; nevertheless, the safety of DNA-mediated immunization protocols still needs to be carefully evaluated before practical application.

show abstract

Mimovirus: a Novel Form of Vaccine That Induces Hepatitis B Virus-Specific Cytotoxic T-Lymphocyte Responses In Vivo

Cited by 18 publications

References 39 publications

Induction of specific immune response and suppression of fertility by B-cell-epitope-based mimovirus vaccine

Induction of specific immune response and suppression of fertility by B-cell-epitope-based mimovirus vaccine

Novel approaches towards conquering hepatitis B virus infection

Long‐term persistence of hepatitis B surface antigenand antibody induced by DNA‐mediated immunization results in liver and kidney lesions in mice

Contact Info

Product

Resources

About